Navigation Links
STEMCELL Technologies Introduces AggreWell™400 for Standardized Embryonic Stem Cell and Induced Pluripotent Stem Cell Research
Date:8/20/2008

STEMCELL Technologies' AggreWell™400 plate is a novel tool for standardizing the generation of uniform embryoid bodies.

Vancouver, British Columbia (PRWEB) August 20, 2008 -- http://www.stemcell.com [STEMCELL Technologies], a leader in specialty cell culture media, cell separation products and ancillary reagents for stem cell research, today announced the release of the AggreWell™400 plates, a revolutionary tool for researchers using embryonic and induced pluripotent stem cells (ESC and iPSC).

"The AggreWell™400 plate standardizes a critical step in the development of embryonic and induced pluripotent stem cells into clinically-relevant mature cells," says Clive Glover, Ph.D., STEMCELL Technologies' Product Manager for Pluripotent Stem Cell Biology. "These cells have been difficult to work with because of the lack of standardized methods to culture and differentiate them. The AggreWell™400 plate is the latest product in STEMCELL Technologies' portfolio that addresses the need for standardized methods and tools for stem cell research."

Many protocols for inducing the development ESC and iPSC into clinically relevant cell types rely on the formation of embryoid bodies (EBs), which are 3-dimensional aggregates of cells. In addition to being labor-intensive, current methods for making EBs results in aggregates that are inconsistent in size and shape, leading to inefficient differentiation.

In contrast, researchers using the AggreWell™400 plates are able to control the size of EBs, enabling them to optimize their differentiation protocols. Additionally the AggreWell™400 plates allow stem cell scientists to easily create large quantities of uniformly-sized EBs

For more information about the AggreWell™400 plates, visit www.stemcell.com/News_Info/aggrewell400_release.aspx.

Contact
Clive Glover, PhD, Product Manager- Pluripotent Stem Cell Biology
STEMCELL Technologies Inc
604 675 7723    
clive.glover(at)STEMCELL.com

About STEMCELL Technologies
STEMCELL Technologies, a leader in specialty cell culture media, cell separation products and ancillary reagents for stem cell research, is a privately-owned biotechnology company based in Vancouver, Canada. Driven by science, STEMCELL Technologies delivers over 800 products to more than 70 countries worldwide including mTeSR™1, a defined, feeder-independent medium for hESC and hiPSC. To learn more about how STEMCELL Technologies helps to make research work, visit www.stemcell.com.

###

Read the full story at http://www.prweb.com/releases/2008/08/prweb1229004.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. Neuralstem Responds to Incorrect StemCells, Inc. Release on Patents
2. VirtualHealth Technologies, Inc., Announces That Its Associate, Private Access, Will Be Partnering with Genetic Alliance To Accelerate Medical Research While Protecting Privacy
3. VirtualHealth Technologies, Inc., Announces Its Associate, Private Access, Appoints Marc Kirshbaum as President & COO
4. Frost & Sullivan Honors ConforMIS for Its Contribution to Personalized Care Through its Customized Implant Development Technologies
5. Wound Management Technologies, Inc. Announces Clarification of Eprint Viewing of Case Report in Advances in Skin and Wound Journal
6. IDE Technologies Signs Contract Worth Over 100 Million Euros to Supply a Desalination Plant to Australia
7. China Medical Technologies Announces Concurrent Offerings of $150 Million of Convertible Senior Notes and Purchased ADSs Pursuant to ADS Issuance and Repurchase Agreements
8. Free White Paper: Hospital Tests Patient Lift Technologies; Improves Quality of Care
9. Wound Management Technologies, Inc. Announces Products to Be Registered in Taiwan
10. On-X Life Technologies Significantly Reduces Study Management Costs with TEMPO from Clinipace
11. VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology: